How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows
Explore why Codexis, Inc.’s latest RNA manufacturing advances could influence scalability, stereochemical control, and future siRNA production economics.
GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery
GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.
Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe’s HTA bodies will now decide whether clinical FCS diagnosis is enough.
FDA fast track for Argo Biopharma’s BW-20805 siRNA puts HAE’s next competitive battleground in focus
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a Shanghai-based clinical-stage RNA interference therapeutics company, has received Fast Track Designation from the U.S. Food and Drug Administration for BW-20805, its investigational small interfering RNA therapy targeting prekallikrein for the prevention of hereditary angioedema attacks. The designation comes as the company runs a global Phase II open-label study […]
Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.